Who is sponsoring NCT03400956?

NCT03400956 is sponsored by Bayer.

What condition does NCT03400956 study?

NCT03400956 studies Uterine Fibroids.

What drugs are being tested in NCT03400956?

Interventions: Vilaprisan (BAY1002670), Placebo.

What is the status of NCT03400956?

NCT03400956 is currently TERMINATED.

Last reviewed 2022-06-30 · How we verify

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

NCT03400956 PHASE3 TERMINATED Results posted

The primary objective of this study was to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids

Details

Lead sponsor	Bayer
Phase	PHASE3
Status	TERMINATED
Enrolment	103
Start date	Wed Jan 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Uterine Fibroids

Interventions

Vilaprisan (BAY1002670)
Placebo

Countries

Japan, Russia, Ukraine, United States, Czechia